Qiagen (NYSE:QGEN) Price Target Raised to $55.00

Qiagen (NYSE:QGEN) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $50.00 to $55.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 20.77% from the stock’s previous close.

QGEN has been the subject of a number of other reports. TD Cowen reiterated a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Barclays set a $40.00 price objective on Qiagen and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Morgan Stanley restated an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. UBS Group started coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 target price on the stock. Finally, Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average price target of $43.93.

Qiagen Trading Up 0.2%

QGEN traded up $0.10 during trading hours on Wednesday, reaching $45.54. The company’s stock had a trading volume of 1,632,435 shares, compared to its average volume of 2,464,141. The stock has a market cap of $9.38 billion, a PE ratio of 23.34, a P/E/G ratio of 4.51 and a beta of 0.61. Qiagen has a fifty-two week low of $32.53 and a fifty-two week high of $57.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The business’s 50-day moving average is $43.59 and its 200-day moving average is $40.20.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts predict that Qiagen will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Hilltop National Bank acquired a new stake in shares of Qiagen in the 2nd quarter valued at $50,000. Integrated Wealth Concepts LLC purchased a new position in shares of Qiagen in the 2nd quarter valued at about $59,000. Allworth Financial LP raised its position in shares of Qiagen by 20.8% during the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock worth $72,000 after acquiring an additional 317 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Qiagen by 46.8% in the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after purchasing an additional 876 shares in the last quarter. Finally, MidFirst Bank acquired a new stake in Qiagen during the fourth quarter worth approximately $154,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.